SPOTLIGHT: Booming vaccine market swells Sanofi's revenue
A sign of the times? When Sanofi-Aventis presented its 2007 results earlier this week, it trumpeted the 14.5 percent sales growth in its vaccines group. That's more than double its pharma growth--and it's without Gardasil, because Sanofi doesn't consolidate its Merck joint venture revenues. Now, vaccines account for 10 percent of group revenues. As In Vivo notes, "Rarely have so many of Big Pharma's slides been devoted to this once-unfashionable category." Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
